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CCL = CC chemokine ligand; C/EBP = CCAAT/enhancer binding protein; CIA = collagen induced arthritis; CXCL = CXC chemokine ligand; DC =
dendritic cell; IFN = interferon; IL = interleukin; IL-17R = IL-17 receptor; MAPK = mitogen-activated protein kinase; NF-κB = nuclear factor-κB; OPG
= osteoprotegerin; RA = rheumatoid arthritis; RANKL = receptor activator of nuclear factor-κB ligand; TNF = tumor necrosis factor; TRAF = tumor
necrosis factor receptor-associated factor.
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Introduction
The cytokine IL-17, originally termed CTLA-8, was isolated
as a CD4-specific transcript from a rodent cDNA library
[1]. Shortly thereafter, IL-17 was discovered in humans,
and its receptor (IL-17R) was cloned and characterized
[2–4]. The most striking feature of both IL-17 and IL-17R
is that they are distinct in sequence from previously
described cytokine/receptor families. However, they are
highly homologous among mice, rats, and humans. In
addition, an IL-17R homolog in zebrafish (termed SEF
[similar expression of FGF genes]) has been described
that functions in embryonic development [5], and
mammalian homologs of SEF were also recently identified
[6,7]. Consequently, IL-17 and IL-17R are now recognized
to be the founding members of an emerging new family
that, in mammals, contains at least six cytokines and five
receptors (Table 1 [8,9]). This review focuses primarily on
the original IL-17 cytokine (also known as IL-17A),
because its roles in bone physiology and arthritis are most
clearly defined, but the biology of the remaining family
members promises to be a fascinating emerging story
within the field of ‘high numbered’ cytokines.
Interleukin-17 and interleukin-17 receptor
structure
Even though IL-17 and IL-17R have been recognized for
many years, there is still much to learn about their
respective structures and functions. IL-17 is secreted
primarily by CD4+ T cells in a mix of both nonglycosylated
and N-glycosylated forms, which migrate in SDS-PAGE at
28 kDa and 33 kDa, respectively [2]. Secreted IL-17
apparently exists as a homodimer, but the specific contact
points between IL-17 subunits or between IL-17 and
IL-17R have never been defined [2,10]. IL-17B and IL-17F
also exist as dimers [10,11]. While the amino acid
sequence of IL-17 did not permit it to be classified as a
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Abstract
IL-17 and its receptor are founding members of an emerging family of cytokines and receptors with
many unique characteristics. IL-17 is produced primarily by T cells, particularly those of the memory
compartment. In contrast, IL-17 receptor is ubiquitously expressed, making nearly all cells potential
targets of IL-17. Although it has only limited homology to other cytokines, IL-17 exhibits
proinflammatory properties similar to those of tumor necrosis factor-α, particularly with respect to
induction of other inflammatory effectors. In addition, IL-17 synergizes potently with other cytokines,
placing it in the center of the inflammatory network. Strikingly, IL-17 has been associated with several
bone pathologies, most notably rheumatoid arthritis.
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member of any known cytokine families, X-ray
crystallographic studies of IL-17F – its closest homolog –
have been performed. Interestingly, the three-dimensional
structure of IL-17F takes on a ‘cystine knot fold’, and hence
resembles the neurotrophin family of growth factors, the
canonical member of which is nerve growth factor [10].
The IL-17R is also particularly interesting because of its
unique primary structure. It contains a single trans-
membrane domain and has an unusually large cytoplasmic
tail [4,12]. This receptor is expressed in most cell types.
One exception is in naïve T cells in mice, which do not
bind IL-17 detectably (Dong C, personal communication).
However, several mouse and human T cell lines do contain
detectable mRNA encoding IL-17R, and so this receptor
may be present in at least low levels in T cells (Gaffen SL,
unpublished data) [12]. As a result of its ubiquitous
expression, nearly all cells are potential targets of this
cytokine, but it is still unclear which cells in vivo are the
most physiologically relevant targets. Most studies to date
have been performed in cells of fibroblast/osteoblast or
epithelial origin, because these appear to be particularly
responsive to IL-17. Although there was originally thought
to be a unique cytokine–receptor relationship between IL-
17 and IL-17R, more recent studies indicate that IL-17F
binds, albeit weakly, to IL-17R [10]. Whereas IL-17 is
composed of a homodimer of identical subunits, the
configuration and stoichiometry of the receptor remain
undefined. In this regard, discrepancies between IL-17
binding constants and concentrations needed to elicit
biologic responses have hinted that an additional subunit
might be involved in IL-17 signaling [10,12]. However,
IL-17R is clearly an essential subunit, because cells from
IL-17R–/– mice fail to bind to IL-17.
Sources, regulation, and biologic functions of
interleukin-17
IL-17 is produced almost exclusively by T lymphocytes,
primarily those of the CD4+ memory (CD45RO+)
compartment [2,13,14]. Consequently, IL-17 does not
obviously polarize to either the T-helper-1 or -2 lineages,
although the literature is somewhat inconsistent in this
regard [15–19]. Consistent with its production by memory
cells, several recent studies have shown that IL-23, which
is produced by dendritic cells (DCs) and acts mainly on
memory T cells, is a potent stimulator of IL-17 secretion
[20,21]. However, it should be noted that signaling
through the T-cell receptor alone is sufficient to promote
IL-17 production even in the absence of DCs or IL-23 (Liu
X, Clements J, Gaffen S, unpublished data), and IL-23
deficient mice are still capable of producing IL-17, albeit at
reduced levels [22]. In addition, IL-15 has been shown to
induce IL-17 production [23].
The gene encoding human IL-17 resides on human
chromosome 6, adjacent to the gene encoding IL-17F
[10], whereas other IL-17 family members are located
elsewhere in the genome [24]. We recently showed that a
minimal regulatory promoter element exists about 250
bases upstream of the transcriptional starting point [25].
In this regard, the signaling pathways leading to IL-17
gene regulation by any of these stimuli are poorly defined,
although several studies indicated that the calcineurin/
NFAT (nuclear factor of activated T cells) pathway is
essential [23,25] (Liu X, Clements J, Gaffen S,
unpublished data). Other studies also indicate a role for
the cAMP/protein kinase A pathway, although this signal
may ultimately converge on NFAT signaling [13,14,26].
Like many cytokines, IL-17 gene expression is likely to be
Table 1
The IL-17 superfamily: cellular sources, receptors, and major functions
Cytokine Other names Cellular source Receptor Major functions
IL-17 IL-17A, CTLA-8 T cells (memory) IL-17R  Inflammation, neutrophil recruitment, 
(also known as, IL-17AR) cytokine secretion, bone metabolism
IL-17B Multiple organs IL-17BR  Cytokine secretion, inflammation
(also known as, IL-17Rh1/Evi27)
IL-17C Unknown Unknown Regulation of Th1 cytokines
IL-17D IL-27 Multiple organs Unknown Cytokine secretion
IL-17E IL-25 Th2 IL-17BR  Regulation of Th2 cytokines
(also known as, IL-17Rh1/Evi27)
IL-17F ML-1 CD4+ T cells and  IL-17R? Angiogenesis, cytokine secretion, 
monocytes regulation of Th1 cytokines
HVS13 vIL-17 Herpesvirus saimiri  IL-17R? Unknown (not required for cellular 
infected cells transformation)
References and further information on this family can be found in the report by Moseley and coworkers [24]. CTLA, cytotoxic T-lymphocyte
associated antigen; IL, interleukin; IL-17R, interleukin-17 receptor; Th, T-helper.242
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at least partially controlled at the level of mRNA stability,
because AU-rich elements exist in the 3′-untranslated
region that could target the transcript for rapid degra-
dation [2,27,28]. Clearly, much still remains to be learned
about how IL-17 expression is controlled biologically.
Functionally, IL-17 has been classified as a pro-
inflammatory mediator, based on its ability to induce a
wide array of inflammatory effectors in target cells (Fig. 1).
Among these are cytokines (e.g. IL-6, tumor necrosis
factor [TNF]-α, IL-1β, IFN-γ, and granulocyte colony-
stimulating factor), chemokines (e.g. CXC chemokine
ligand [CXCL]2/MIP-2/IL-8, CXCL1/Groα/KC, CC
chemokine ligand [CCL]2/MCP-1, CCL5/RANTES, and
CXCL5/LIX), and other effectors (e.g. cyclo-oxygenase-2,
prostaglandin E2, nitric oxide, and intercellular adhesion
molecule-1; for review [8]). Moreover, IL-17 cooperates
either additively or synergistically with various inflammatory
cytokines or agonists, thus placing this cytokine in the
midst of a complex network that amplifies inflammation
(see below). In this sense, IL-17 appears to function as an
activator of the innate immune system, analogous to TNF-
α and IL-1β, with which it shares many target genes.
However, because IL-17 is produced by T cells rather
than by monocytes or other innate cells, it presumably
comes into play during adaptive or memory immune
responses. Consequently, the function of IL-17 may be to
trigger innate immune responses shortly after a second
encounter with antigen, when the memory response is
activated but when concentrations of antigen are still too
low to trigger a full-scale innate immune response.
Interleukin-17 as a synergistic cytokine
A prominent feature of IL-17 is its ability to synergize with
other cytokines to enhance inflammation (for review [29]).
In particular, IL-17 has been shown to synergize with IL-1β
and TNF-α to drive expression of numerous inflammatory
effectors [18,30–35]. IL-17 also synergizes with CD40
ligand, a TNF receptor family member, to upregulate target
gene expression [36]. Similarly, IL-17 synergizes with
IFN-γ to promote chemokine gene expression [37].
Microarray analysis of an osteoblast cell line examining
synergy between IL-17 and TNF-α revealed that all genes
induced by IL-17 alone were induced more potently in
cooperation with TNF-α. This finding suggests that a
primary function of IL-17 may be to amplify ongoing
inflammatory responses [34,35].
Although the molecular mechanisms that mediate cytokine
synergy are not fully understood, several have been
proposed. For example, IL-17 cooperates with TNF-α or
IL-1β to enhance mRNA stabilization of the CXCL1/Groα/
KC chemokine transcript in peritoneal mesothelial cells
[33]. In its synergy with CD40 ligand, IL-17 upregulates
expression of CD40, thus enhancing all CD40 ligand
dependent responses [36]. However, this is not true of
IL-17 synergy with TNF-α, because IL-17 does not appear
to enhance TNF receptor expression in osteoblasts [35].
Although IL-17 synergy with IFN-γ has been reported to
occur via enhancement of the nuclear factor-κB (NF-κB)
pathway [37], this is not the mechanism by which IL-17
synergizes with TNF-α [35]. Rather, we recently showed
that IL-17 synergizes with TNF-α to promote IL-6
production by upregulating expression of CCAAT/
enhancer binding protein (C/EBP)δ (also known as
NF-IL-6β), a member of the bZIP family of transcription
factors. The conserved C/EBP site in the IL-6 proximal
promoter is essential for expression of IL-6, and thus
cooperative upregulation of C/EBPδ mediated by IL-17
and TNF-α helps in turn to enhance transcription of the
IL-6 gene [35,38]. Another report suggested that
p38/mitogen-activated protein kinase (MAPK) may be a
target of cooperative signaling between IL-17 and TNF-α
[39]. In addition to transcription and RNA stability,
synergistic signaling may affect regulation of chromatin
Figure 1
Opposing roles of IL-17 in bone turnover. IL-17 is produced by T cells
(particularly memory T cells), and acts on a wide variety of target cells
to trigger expression of inflammatory effectors. Most of these effectors
have been shown to have an impact on bone metabolism. Those
factors that promote osteoclastogenesis indirectly favor bone
destruction. Conversely, chemotactic factors promote neutrophil
recruitment and activation, which can exert both bone protective and
bone destructive effects. G-CSF, granulocyte colony-stimulating factor;
ICAM, intercellular adhesion molecule; IFN, interferon; IL, interleukin;
LIX, LPS-inducible CXC chemokine; MCP, monocyte chemotactic
protein; PGE2, prostaglandin E2; RANKL, receptor activator of nuclear
factor-κB ligand; TNF, tumor necrosis factor.243
remodeling, cytokine secretion, and possibly other levels
of gene or protein regulation. Given the proclivity of IL-17
to function in concert with other cytokines, it will be very
important to dissect the multiple mechanisms by which
this cytokine promotes cooperative/synergistic signaling.
The immune system and bone homeostasis
Bone undergoes a continuous cycle of remodeling that is
required for its maintenance and healing, and recent
advances have elucidated many of the molecular
mechanisms that regulate or have an impact on this
process (for review [40,41]). Two major types of cells are
involved in bone remodeling. Osteoblasts, cells that are
crucially involved in bone formation, are derived from
mesenchymal stem cells and are closely related to
fibroblasts, adipocytes, and muscle cells [42].
Osteoclasts, the cells responsible for bone degradation,
are derived from hematopoietic precursors, and are thus
related to macrophages and DCs [43]. In normal
physiology, osteoblasts trigger the formation of
osteoclasts, thus helping to maintain homeostasis in bone
remodeling. Conversely, the bone resorbing activity of
osteoclasts causes the release of various growth factors
and bone cell mitogens that induce proliferation and
differentiation of osteoblasts [40]. Importantly, a number of
pathologic conditions adversely affect bone by altering the
balance between osteoblast and osteoclast activity,
causing localized or systemic osteoporosis (or, less
frequently, osteopetrosis) [41,44]. Such conditions may
have severe medical and economic consequences. For
example, it is estimated that as many as 15% of adults
suffer from periodontal disease severe enough to cause
tooth loss, and the acute crippling in advanced rheuma-
toid arthritis (RA) can have devastating consequences for
the quality of life of its victims. Therefore, it is paramount to
understand the network of factors that control bone homeo-
stasis, in order to develop optimal avenues of intervention
and treatment in diseases that involve bone loss.
Recent discoveries have significantly advanced our
understanding of the molecular basis for bone turnover
(for review [41,45]). At a molecular level, osteoblasts
express a receptor called RANKL (receptor activator of
NF-κB ligand; also termed osteoprotegerin [OPG] ligand).
RANKL is a member of the TNF receptor superfamily and
is central in controlling osteoclastogenesis, and hence
bone degradation [46,47]. RANKL acts by engaging its
counter-receptor RANK (receptor activator of NF-κB) on
osteoclast precursors, thereby triggering their maturation
and activation in conjunction with signals from the growth
factor macrophage colony-stimulating factor [48]. The
interaction between RANK and RANKL can be further
modulated by a soluble ‘decoy’ receptor called OPG,
which also binds to RANK but does not induce osteo-
clastogenesis [49]. The relative balance between OPG
and RANKL dictates the magnitude of osteoclastogenesis.
For many years it has been recognized that the immune
system exerts a profound effect on bone cell activity,
explaining why infectious diseases such as periodontal
disease or autoimmune diseases such as RA are
associated with bone destruction (for review [50]). In
particular, both T cells and inflammatory cytokines have
been implicated in this process. Interestingly, activated T
cells inducibly express RANKL, and can thus bypass
osteoblasts in triggering osteoclastogenesis, ultimately
tipping the balance in favor of bone destruction [51].
Inflammatory cytokines such as TNF-α or IL-1β (and IL-17;
see below) act on osteoblasts to upregulate RANKL,
either directly or indirectly through the production of other
cytokines/chemokines [52]. Clinical strategies to block
cytokines such as TNF-α and IL-1β have been quite
effective in treating RA, and efforts are underway to
influence the RANK–RANKL axis directly through the
therapeutic use of OPG [45,53].
Evidence for a role of interleukin-17 in bone
and arthritis
A number of studies have implicated IL-17 in bone
metabolism. Most prominently, IL-17 is found at
significantly elevated levels in the synovial fluid of patients
with RA, and is present in osteoarthritic joints as well [54].
IL-17 has also been found in patients with relatively severe
periodontitis, where it could potentially contribute to bone
destruction [55]. In addition, IL-17 exerts many of its
effects on bone cells in culture [54,56], including
induction of both membrane-bound and soluble RANKL in
primary mouse osteoblast/stromal cell cultures [52]. IL-17
is strongly implicated in several mouse models of RA.
Enhancement of RANKL following IL-17 stimulation was
not observed in several osteoblast or stromal cell lines,
including MC3T3-E1 or ST-2 cells (Kirkwood KL, personal
communication). However, in vivo bone erosion mediated
by over-expression of IL-17 has been shown to occur
through alterations in the RANKL/OPG ratio [57]. Further-
more, IL-17 knockout mice are highly resistant to collagen
induced arthritis (CIA) [58], and blocking IL-17 reduces
inflammatory symptoms and bone loss in mice with CIA
[59,60]. Conversely, excess IL-17, as provided by adeno-
virus-mediated gene vectors, exacerbates disease [61–64].
Remarkably, mice deficient in the T cell costimulatory
molecule ICOS (inducible co-stimulator) are also profoundly
resistant to CIA, and the only cytokine deficiency detected
in these mice was a reduction in IL-17 [65].
It is also striking that most IL-17-induced factors tend to
be bone resorptive in nature (Fig. 1; for review [66]). For
example, IL-6 has been shown to be a contributing factor
to estrogen mediated bone loss [67] as well as bone loss
due to periodontal disease [68]. Similarly, CXCL8/IL-8,
prostaglandin E2, and nitric oxide have all been implicated
in the pathogenesis of periodontitis [69]. However, the
role played by neutrophils in bone turnover is more
Available online http://arthritis-research.com/content/6/6/240244
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complex. During chronic inflammation, neutrophils are
thought to contribute to bone destruction. However,
neutrophils are generally considered to be bone protective
in the context of periodontal disease-induced bone loss
(for review [70,71]). IL-17 is a potent activator of
neutrophil recruitment and activation, due in large part to
its ability to promote chemokine secretion. Thus, IL-17
could potentially play a positive role in situations where
neutrophil activity is bone protective.
In summary, IL-17 clearly has an impact on bone
metabolism, and in the context of arthritis it appears to be
a bone destructive cytokine.
Interleukin-17 in other diseases
IL-17 has been implicated in numerous other disease
settings. Intriguingly, IL-17 is highly homologous to an open
reading frame found in the T cell tropic Herpesvirus saimiri,
although its physiologic significance within the context of
this virus remains unknown [12,72]. However, addition of
the gene encoding murine IL-17 into the vaccinia virus
enhanced its virulence significantly, suggesting a possible
pathogenic role for this cytokine in viral infections [73]. The
role played by IL-17 in tumorigenesis is complex. IL-17 was
shown to promote growth and tumorigenicity of human
cervical tumors in athymic (nude) mice [74]. In contrast, IL-
17 also inhibited the growth of hematopoietic tumors in
immunocompetent but not nude mice [75]. IL-17 has also
been found at elevated levels in the context of bacterial
infections, such as periodontitis [55] and Helicobacter
pylori infections [76]. Finally, IL-17 plays an important role
in immune responses in the lung. Specifically, IL-17R–/–
mice are highly susceptible to lung airway infections due to
a failure to recruit neutrophils [77]. Human bronchial
epithelial cells induce chemokines following IL-17
stimulation, and local administration of IL-17 in mouse lung
tissue causes neutrophil recruitment and increases in
elastase and myeloperoxidase activities (for review
[78,79]). Finally, data from IL-17–/– and IL-17R–/– mice
indicate that this cytokine is also involved in a variety of
other T cell dependent events. For example, delayed type
hypersensitivity and contact hypersensitivity responses are
severely impaired in IL-17–/– mice [80]. Interestingly,
attempts to over-express IL-17 transgenically have not
been successful, perhaps because of a generalized
inflammation that is lethal to developing embryos [81].
Thus, IL-17 is important for numerous immune functions
related to regulation of inflammation, and can play both
pathogenic and protective roles in vivo.
Interleukin-17 and interleukin-17 receptor
signaling
The signaling mechanisms used by IL-17 to regulate its
downstream targets are surprisingly poorly defined. As
indicated above, the IL-17R is the founding member of a
new subclass of cytokine receptors that do not bear
homology to type I or II cytokine receptors, TNF receptors,
or other receptor families [12,82]. Because so little is
known about signaling pathways induced by this class of
receptor, few predictions can be made based its primary
amino acid structure.
Recently, however, it was suggested that IL-17 receptors
may contain a putative TIR (Toll/IL-1 receptor) domain in
the intracellular region [7], and the IL-17R tail also
contains at least two putative TNF receptor-associated
factor (TRAF)-binding domains (Gaffen SL, unpublished
observations) [83]. Although early reports suggested that
IL-17 activates the transcription factor NF-κB [12], careful
comparisons show that NF-κB induction is generally quite
modest as compared with that triggered by TNF-α or Toll-
like receptor agonists [35]. Other signaling pathways
implicated in IL-17 signaling include the MAPK, protein
kinase A and JAK/STAT (Janus kinase/signal transducer
and activator of transcription) pathways (for review [8]).
However, only in a few cases have these pathways been
linked to specific signaling outcomes. One study showed
convincingly that IL-17 recruits the adaptor molecule
TRAF6 in murine embryonic fibroblast cells, which are
among the few cell types that induce NF-κB strongly. In
these cells, TRAF6 lies upstream of signaling leading to IL-
6 and intercellular adhesion molecule-1 expression [84].
Based on paradigms in the TNF and Toll-like receptors,
TRAF6 probably also lies upstream of MAPK signaling,
although this remains to be proven for the IL-17R [85]. In
another study, the IL-17-induced MAPK pathway was
linked to IL-6 gene expression via stabilization of IL-6
mRNA [39]. Similarly, IL-17 alone mediates cyclo-
oxygenase-2 mRNA stability in a p38-MAPK dependent
manner [86]. To date, no detailed mutagenesis studies of
IL-17R have been performed, and so regions of the
receptor required for activation of various signaling
pathways have not yet been determined.
Conclusion
IL-17 is the prototypical member of a fascinating new
family of cytokines. Although it is clear that IL-17 is
proinflammatory in nature, its physiologic significance is
only just beginning to be elucidated. The unique structure
of IL-17 and its receptor hint at exciting new discoveries in
the area of signal transduction as well as potential
therapeutic intervention strategies. With respect to
This article is the second in a review series on
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arthritis, IL-17 appears to be largely pathogenic. However,
findings in IL-17 and IL-17R knockout mice indicate a
nonredundant role for this cytokine in regulating host
immunity to infection. Future work on the IL-17 family will
no doubt yield many surprises, and will probably establish
new paradigms for cytokine biology.
Competing interests
The author has received travel reimbursement and an
honorarium from Amgen Corporation, Seattle, WA, USA.
Acknowledgments
We thank Drs Austin Gurney (Genentech, South San Francisco, CA,
USA) and Joel Tocker (Amgen Corporation, Seattle, WA, USA) for
helpful suggestions. We also thank Drs Chen Dong (University of
Washington, Seattle, WA, USA) and KL Kirkwood (University of Michi-
gan, Ann Arbor, MI, USA) for sharing unpublished information.
This work was supported by the US National Institutes of Health
(AI49329) and the Arthritis Foundation.
References
1. Rouvier E, Luciani M-F, Mattei M-G, Denizot F, Golstein P: CTLA-
8, cloned from an activated T cell, bearing AU-rich messenger
RNA instability sequences, and homologous to a Herpesvirus
Saimiri gene. J Immunol 1993, 150:5445-5456.
2. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S,
Maat C, Pin J-J, Garrone P, Garcia E, Saeland S, et al.: T cell
interleukin-17 induces stromal cells to produce proinflamma-
tory and hematopoietic cytokines. J Exp Med 1996, 183:2593-
2603.
3. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs
MK, Armitage RJ: Cutting Edge: Human IL-17: A novel cytokine
derived from T cells. J Immunol 1995, 155:5483-5486.
4. Yao Z, Spriggs MK, Derry JMJ, Strockbine L, Park LS, VandenBos
T, Zappone J, Painter SL, Armitage RJ: Molecular characteriza-
tion of the human interleukin-17 receptor. Cytokine 1997, 9:
794-800.
5. Tsang M, Friesel R, Kudoh T, Dawid IB: Identification of Sef, a
novel modulator of FGF signalling. Nat Cell Biol 2002, 4:165-
169.
6. Yang RB, Ng CK, Wasserman SM, Komuves LG, Gerritsen ME,
Topper JN: A novel interleukin-17 receptor-like protein identi-
fied in human umbilical vein endothelial cells antagonizes
basic fibroblast growth factor-induced signaling. J Biol Chem
2003, 278:33232-33238.
7. Xiong S, Zhao Q, Rong Z, Huang G, Huang Y, Chen P, Zhang S,
Liu L, Chang Z: hSef inhibits PC-12 cell differentiation by inter-
fering with Ras-mitogen-activated protein kinase MAPK sig-
naling. J Biol Chem 2003, 278:50273-50282.
8. Aggarwal S, Gurney AL: IL-17: A prototype member of an
emerging cytokine family. J Leukoc Biol 2002, 71:1-8.
9. Eberl M: Don’t count your interleukins before they’ve hatched.
Trends Immunol 2002, 23:341-342.
10. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, Maruoka
M, Mao W, Foster J, Kelley RF, et al.: IL-17s adopt a cystine knot
fold: structure and activity of a novel cytokine, IL-17F, and
implications for receptor binding. EMBO J 2001, 20:5332-
5341.
11. Shi Y, Ullrich SJ, Zhang J, Connolly K, Grzegorzewski KJ, Barber
MC, Wang W, Wathen K, Hodge V, Fisher CL, et al.: A novel
cytokine receptor-ligand pair. Identification, molecular charac-
terization, and in vivo immunomodulatory activity. J Biol Chem
2000, 275:19167-19176.
12. Yao Z, Fanslow WC, Seldin MF, Rousseau A-M, Painter SL,
Comeau MR, Cohen JI, Spriggs MK: Herpesvirus Saimiri
encodes a new cytokine, IL-17, which binds to a novel
cytokine receptor. Immunity 1995, 3:811-821.
13. Shin HC, Benbernou N, Fekkar H, Esnault S, Guenounou M: Reg-
ulation of IL-17, IFN-gamma and IL-10 in human CD8+ T cells
by cyclic AMP-dependent signal transduction pathway.
Cytokine 1998, 10:841-850.
14. Shin HC, Benbernou N, Esnault S, Guenounou M: Expression of
IL-17 in human memory CD45RO+ T lymphocytes and its reg-
ulation by protein kinase A pathway. Cytokine 1999, 11:257-
266.
15. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA,
Bos JD: Interleukin-17 and interferon-γ γ synergize in the
enhancement of proinflammatory cytokine production by
human keratinocytes. J Invest Dermatol 1998, 111:645-649.
16. Aarvak T, Chabaud M, Miossec P, Natvig JB: IL-17 is produced
by some proinflammatory Th1/Th0 cells but not by Th2 cells.
J Immunol 1999, 162:1246-1251.
17. Chabaud M, Page G, Miossec P: Enhancing effect of IL-1, IL-17,
and TNF-alpha on macrophage inflammatory protein-3alpha
production in rheumatoid arthritis: regulation by soluble
receptors and Th2 cytokines. J Immunol 2001, 167:6015-6020.
18. Albanesi C, Cavani A, Girolomoni G: IL-17 is produced by
nickel-specific T lymphocytes and regulates ICAM-1 expres-
sion and chemokine production in human keratinocytes: syn-
ergistic or antagonistic effects with IFN-γ γ and TNF-α α. J
Immunol 1999, 162:494-502.
19. Infante-Duarte C, Horton HF, Byrne MC, Kamradt T: Microbial
lipopeptides induce the production of IL-17 in Th cells. J
Immunol 2000, 165:6107-6115.
20. Happel KI, Zheng M, Young E, Quinton LJ, Lockhart E, Ramsay
AJ, Shellito JE, Schurr JR, Bagby GJ, Nelson S, et al.: Cutting
edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expres-
sion in response to Klebsiella pneumoniae infection. J
Immunol 2003, 170:4432-4436.
21. Aggarwal S, Ghilardi N, Xie MH, De Sauvage FJ, Gurney AL:
Interleukin 23 promotes a distinct CD4 T cell activation state
characterized by the production of interleukin 17. J Biol Chem
2003, 278:1910-1914.
22. Ghilardi N, Kljavin N, Chen Q, Lucas S, Gurney A, de Sauvage FJ:
Compromised humoral and delayed-type hypersensitivity
responses in IL-23-deficient mice. J Immunol 2004, 172:2827-
2833.
23. Ziolkowska M, Koc A, Luszczukiewicz G, Ksiezopolksa-Pietrzak K,
Klimczak E, Chwalinska-Sadowska H, Maslinski W: High levels of
IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-
17 production via cyclosporin A-sensitive mechanism. J
Immunol 2000, 164:2832-2838.
24. Moseley TA, Haudenschild DR, Rose L, Reddi AH: Interleukin-17
family and IL-17 receptors. Cytokine Growth Factor Rev 2003,
14:155-174.
25. Liu X, Lin X, Gaffen SL: Crucial role for nuclear factor of acti-
vated T cells (NFAT) in T cell receptor-mediated regulation of
the human interleukin-17 gene. J Biol Chem 2004, Sep 30
[Epub ahead of print]
26. Sheridan CM, Heist EK, Beals CR, Crabtree GR, Gardner P: Protein
kinase A negatively modulates the nuclear accumulation of NF-
ATc1 by priming for subsequent phosphorylation by glycogen
synthase kinase-3. J Biol Chem 2002, 277:48664-48676.
27. Yao Z, Timour M, Painter S, Fanslow W, Spriggs M: Complete
nucleotide sequence of the mouse CTLA8 gene. Gene 1996,
168:223-225.
28. Lindsten T, June CH, Ledbetter JA, Stella G, Thompson CB: Reg-
ulation of lymphokine messenger RNA stability by a surface-
mediated T-cell activation pathway. Science 1989, 244:
339-343.
29. Miossec P: Interleukin-17 in rheumatoid arthritis: if T cells
were to contribute to inflammation and destruction through
synergy. Arthritis Rheum 2003, 48:594-601.
30. Laan M, Cui A-H, Hoshino H, Lötvall J, Sjöstrand M, Gruenert DC,
Skoogh B-E, Lindén A: Neutrophil recruitment by human IL-17
via C-X-C chemokine release in the airways. J Immunol 1999,
162:2347-2352.
31. Maertzdorf J, Osterhaus AD, Verjans GM: IL-17 expression in
human herpetic stromal keratitis: modulatory effects on
chemokine production by corneal fibroblasts. J Immunol 2002,
169:5897-5903.
32. Van Bezooijen RL, Papapoulos SE, Lowik CW: Effect of inter-
leukin-17 on nitric oxide production and osteoclastic bone
resorption: is there dependency on nuclear factor-kappaB
and receptor activator of nuclear factor kappaB
(RANK)/RANK ligand signaling? Bone 2001, 28:378-386.
33. Witowski J, Pawlaczyk K, Breborowicz A, Scheuren A, Kuzlan-
Pawlaczyk M, Wisniewska J, Polubinska A, Friess H, Gahl GM,
Available online http://arthritis-research.com/content/6/6/240246
Frei U, et al.: IL-17 stimulates intraperitoneal neutrophil infil-
tration through the release of GRO alpha chemokine from
mesothelial cells. J Immunol 2000, 165:5814-5821.
34. Ruddy MJ, Shen F, Smith J, Sharma A, Gaffen SL: Interleukin-17
regulates expression of the CXC chemokine LIX/CXCL5 in
osteoblasts: Implications for inflammation and neutrophil
recruitment. J Leukoc Biol 2004, 76:135-144.
35. Ruddy MJ, Wong GC, Liu XK, Yamamoto H, Kasayama S, Kirk-
wood KL, Gaffen SL: Functional cooperation between inter-
leukin-17 and tumor necrosis factor-α α is mediated by
CCAAT/enhancer binding protein family members. J Biol
Chem 2004, 279:2559-2567.
36. Woltman AM, de Haij S, Boonstra JG, Gobin SJ, Daha MR, van
Kooten C: Interleukin-17 and CD40-ligand synergistically
enhance cytokine and chemokine production by renal epithe-
lial cells. J Am Soc Nephrol 2000, 11:2044-2055.
37. Takaya H, Andoh A, Makino J, Shimada M, Tasaki K, Araki Y,
Bamba S, Hata K, Fujiyama Y, Bamba T: Interleukin-17 stimu-
lates chemokine (interleukin-8 and monocyte chemoattrac-
tant protein-1) secretion in human pancreatic periacinar
myofibroblasts. Scand J Gastroenterol 2002, 37:239-245.
38. Eickelberg O, Pansky A, Mussmann R, Bihl M, Tamm M, Hilde-
brand P, Perruchoud AP, Roth M: Transforming growth factor-
beta1 induces interleukin-6 expression via activating
protein-1 consisting of JunD homodimers in primary human
lung fibroblasts. J Biol Chem 1999, 274:12933-12938.
39. Tokuda H, Kanno Y, Ishisaki A, Takenaka M, Harada A, Kozawa O:
Interleukin (IL)-17 enhances tumor necrosis factor-alpha-
stimulated IL-6 synthesis via p38 mitogen-activated protein
kinase in osteoblasts. J Cell Biochem 2004, 91:1053-1061.
40. Baker P: The role of immune responses in bone loss during
periodontal disease. Microbes Infect 2000, 2:1181-1192.
41. Theill L, Boyle W, Penninger J: RANK-L and RANK: T cells, bone
loss and mammalian evolution. Annu Rev Immunol 2002, 20:
795-823.
42. Ducy P, Schinke T, Karsenty G: The osteoblast: a sophisticated
fibroblast under central surveillance. Science 2000, 289:1501-
1504.
43. Teitelbaum S: Bone resorption by osteoclasts. Science 2000,
289:1504-1508.
44. Rodan GA, Martin TJ: Therapeutic approaches to bone dis-
eases. Science 2000, 289:1508-1514.
45. Nakashima T, Wada T, Penninger JM: RANKL and RANK as
novel therapeutic targets for arthritis. Curr Opin Rheumatol
2003, 15:280-287.
46. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T,
Elliott R, Colombero A, Elliott G, Scully S, et al.: Osteoprotegerin
ligand is a cytokine that regulates osteoclast differentiation
and activation. Cell 1998, 93:165-176.
47. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli S,
Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, et al.: OPGL is a
key regulator of osteoclastogenesis, lymphocyte development
and lymph-node organogenesis. Nature 1999, 397:315-323.
48. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe
S, Elliott R, Scully S, Van G, et al.:  RANK is the intrinsic
hematopoietic cell surface receptor that controls osteoclasto-
genesis and regulation of bone mass and calcium metabo-
lism. Proc Natl Acad Sci USA 2000, 97:1566-1571.
49. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy
R, Nguyen HQ, Wooden S, Bennett L, Boone T, et al.: Osteopro-
tegerin: a novel secreted protein involved in the regulation of
bone density. Cell 1997, 89:309-319.
50. Grcevic D, Katavic V, Lukic IK, Kovacic N, Lorenzo JA, Marusic A:
Cellular and molecular interactions between immune system
and bone. Croat Med J 2001, 42:384-392.
51. Kong Y-Y, Gelge U, Sarosi H, Bolon B, Tafuri A, Morony S, Cap-
pareli C, Li J, Elliott R, McCabe S, et al.: Activated T cells regu-
late bone loss and joint destruction in adjuvant arthritis
through osteoprotegerin ligand. Nature 1999, 402:304-309.
52. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K,
Sasaki H, Sakai H: Protein expression and functional differ-
ence of membrane-bound and soluble receptor activator of
NF-kappaB ligand: modulation of the expression by
osteotropic factors and cytokines. Biochem Biophys Res
Commun 2000, 275:768-775.
53. Choy EH, Panayi GS: Cytokine pathways and joint inflamma-
tion in rheumatoid arthritis. N Engl J Med 2001, 344:907-916.
54. van Bezooijen RL, Farih-Sips HCM, Papapoulos SE, Löwik
CWGM: Interleukin-17: a new bone acting cytokine in vitro. J
Bone Miner Res 1999, 14:1513-1521.
55. Johnson RB, Wood N, Serio FG: Interleukin-11 and IL-17 and
the pathogenesis of periodontal disease. J Periodontol 2004,
75:37-43.
56. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L,
Miossec P: Human interleukin 17: a T cell-derived proinflam-
matory cytokine produced by the rheumatoid synovium.
Arthritis Rheum 1999, 42:963-970.
57. Lubberts E, van den Bersselaar L, Oppers-Walgreen B,
Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, Joosten LA, van
den Berg WB: IL-17 promotes bone erosion in murine colla-
gen-induced arthritis through loss of the receptor activator of
NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003,
170:2655-2662.
58. Nakae S, Nambu A, Sudo K, Iwakura Y: Suppression of immune
induction of collagen-induced arthritis in IL-17-deficient mice.
J Immunol 2003, 171:6173-6177.
59. Lubberts E, Joosten LAB, Chabaud M, van den Bersselaar L,
Oppers B, Coenen-de Roo CJJ, Richards CD, Miossec P, van den
Berg WB: IL-4 gene therapy for collagen arthritis suppresses
synovial IL-17 and osteoprotegerin ligand and prevents bone
erosion. J Clin Invest 2000, 105:1697-1710.
60. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersse-
laar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB: Treat-
ment with a neutralizing anti-murine interleukin-17 antibody
after the onset of collagen-induced arthritis reduces joint
inflammation, cartilage destruction, and bone erosion. Arthritis
Rheum 2004, 50:650-659.
61. Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P:
IL-17 derived from juxta-articular bone and synovium con-
tributes to joint degradation in rheumatoid arthritis. Arthritis
Res 2001, 3:168-177.
62. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L,
Coenen-de Roo CJ, Kolls JK, Schwarzenberger P, van de Loo FA,
van den Berg WB: IL-1-independent role of IL-17 in synovial
inflammation and joint destruction during collagen-induced
arthritis. J Immunol 2001, 167:1004-1013.
63. Lubberts E, Joosten LA, van de Loo FA, Schwarzenberger P, Kolls
J, van den Berg WB: Overexpression of IL-17 in the knee joint
of collagen type II immunized mice promotes collagen arthri-
tis and aggravates joint destruction. Inflamm Res 2002, 51:
102-104.
64. Lubberts E, Joosten LA, van de Loo FA, van den Gersselaar LA,
van den Berg WB: Reduction of interleukin-17-induced inhibi-
tion of chondrocyte proteoglycan synthesis in intact murine
articular cartilage by interleukin-4. Arthritis Rheum 2000, 43:
1300-1306.
65. Nurieva RI, Treuting P, Duong J, Flavell RA, Dong C: Inducible
costimulator is essential for collagen-induced arthritis. J Clin
Invest 2003, 111:701-706.
66. McCauley LK: Transgenic mouse models of metabolic bone
disease. Curr Opin Rheumatol 2001, 13:316-325.
67. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams
JS, Boyce B, Broxmeyer H, Manolagas S: Increased osteoclast
development after estrogen loss: mediated by interleukin-6.
Science 1992, 257:88-91.
68. Baker PJ, Dixon M, Evans RT, Dufour L, Johnson E, Roopenian
DC: CD4+ T cells and the proinflammatory cytokines gamma
interferon and interleukin-6 contribute to alveolar bone loss in
mice. Infect Immun 1999, 67:2804-2809.
69. Page R, Kornman K (editors): Periodontology 2000. Copenhagen:
Munksgaard; 1997.
70. Kantarci A, Oyaizu K, Van Dyke TE: Neutrophil-mediated tissue
injury in periodontal disease pathogenesis: findings from local-
ized aggressive periodontitis. J Periodontol 2003, 74:66-75.
71. Baker PJ, DuFour L, Dixon M, Roopenian DC: Adhesion mole-
cule deficiencies increase Porphyromonas gingivalis-induced
alveolar bone loss in mice. Infect Immun 2000, 68:3103-3107.
72. Knappe A, Hiller C, Niphuis H, Fossiez F, Thurau M, Wittmann S,
Kuhn EM, Lebecque S, Banchereau J, Rosenwirth B, et al.: The
interleukin-17 gene of herpesvirus saimiri. J Virol 1998, 72:
5797-5801.
73. Patera AC, Pesnicak L, Bertin J, Cohen JI: Interleukin 17 modu-
lates the immune response to vaccinia virus infection. Virology
2002, 299:56-63.
Arthritis Research & Therapy    Vol 6 No 6 Gaffen247
74. Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, Sastre-
Garau X, Couturier J, Mosseri V, Vives V, et al.: Interleukin 17, a
T-cell-derived cytokine, promotes tumorigenicity of human
cervical tumors in nude mice. Cancer Res 1999, 59:3698-
3704.
75. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautes-Fridman
C, Fossiez F, Haicheur N, Fridman WH, Tartour E: Interleukin-17
inhibits tumor cell growth by means of a T-cell- dependent
mechanism. Blood 2002, 99:2114-2121.
76. Luzza F, Parrello T, Monteleone G, Sebkova L, Romano M, Zarrilli
R, Imeneo M, Pallone F: Up-regulation of IL-17 is associated
with bioactive IL-8 expression in Helicobacter pylori-infected
human gastric mucosa. J Immunol 2000, 165:5332-5337.
77. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzen-
berger P, Oliver P, Huang W, Zhang P, Zhang J, et al.: Require-
ment of interleukin 17 receptor signaling for lung CXC
chemokine and granulocyte colony-stimulating factor expres-
sion, neutrophil recruitment, and host defense. J Exp Med
2001, 194:519-527.
78. Linden A, Adachi M: Neutrophilic airway inflammation and IL-
17. Allergy 2002, 57:769-775.
79. Schwarzenberger P, La Russa V, Miller A, Ye P, Huang W, Zieske
A, Nelson S, Bagby GJ, Stoltz S, Mynatt RL, et al.: IL-17 stimu-
lates granulopoiesis in mice: Use of an alternate, novel gene
therapy-derived method for in vivo evaluation of cytokines. J
Immunol 1998, 161:6383-6389.
80. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I,
Sekikawa K, Asano M, Iwakura Y: Antigen-specific T cell sensiti-
zation is impaired in IL-17-deficient mice, causing suppres-
sion of allergic cellular and humoral responses. Immunity
2002, 17:375-387.
81. Pan G, French D, Mao W, Maruoka M, Risser P, Lee J, Foster J,
Aggarwal S, Nicholes K, Guillet S, et al.: Forced expression of
murine IL-17E induces growth retardation, jaundice, a Th2-
biased response, and multiorgan inflammation in mice. J
Immunol 2001, 167:6559-6567.
82. Ozaki K, Leonard WJ: Cytokine and cytokine receptor
pleiotropy and redundancy. J Biol Chem 2002, 277:29355-
29358.
83. Pullen SS, Dang TT, Crute JJ, Kehry MR: CD40 signaling
through tumor necrosis factor receptor-associated factors
(TRAFs). Binding site specificity and activation of downstream
pathways by distinct TRAFs. J Biol Chem 1999, 274:14246-
14254.
84. Schwandner R, Yamaguchi K, Cao Z: Requirement of tumor
necrosis factor-associated factor (TRAF)6 in interleukin 17
signal transduction. J Exp Med 2000, 191:1233-1239.
85. Akira S: Toll-like receptors and innate immunity. Adv Immunol
2001, 78:1-56.
86. Faour WH, Mancini A, He QW, Di Battista JA: T-cell-derived
interleukin-17 regulates the level and stability of cyclooxyge-
nase-2 (COX-2) mRNA through restricted activation of the
p38 mitogen-activated protein kinase cascade: role of distal
sequences in the 3’-untranslated region of COX-2 mRNA. J
Biol Chem 2003, 278:26897-26907.
Available online http://arthritis-research.com/content/6/6/240